GlassScriptPhysician profile
Taylor C Dieter
NPI 1013430420
$8,577.41
in general payments reported to CMS, 2019-2025
26 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.08 · 2020: $33.03 · 2021: $2,070 · 2022: $3,983 · 2023: $870 · 2024: $950 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,015.66 | 2021-2025 | |
| Almirall LLC | $1,142.41 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $569.58 | 2019-2022 | |
| Amgen INC. | $389.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $341.13 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $340.86 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $319.23 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $245.98 | 2021-2022 | |
| Galderma Laboratories, L.P. | $244.60 | 2021-2024 | Dysport |
| Lilly USA, LLC | $222.74 | 2021-2022 | |
| Ucb, INC. | $217.47 | 2021-2022 | |
| Pfizer INC. | $192.21 | 2021-2022 | |
| Janssen Biotech, INC. | $187.92 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $185.99 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $171.10 | 2021-2023 | Neo-Synalar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $160.13 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $143.27 | 2021 | |
| Leo Pharma INC. | $127.64 | 2021-2022 | |
| Epi Health, LLC | $90.38 | 2021-2022 | |
| Genzyme Corporation | $69.27 | 2022 | |
| Journey Medical Corporation | $66.29 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.44 | 2022 | |
| Mission Pharmacal Company | $33.03 | 2020 | |
| Arcutis Biotherapeutics, INC. | $19.37 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Dieter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.